The Circulating Biomarkers Conference 2015 is taking place in Glasgow on 30th September and 1st October and will be held in partnership with the Institute of Cancer Sciences at the University of Glasgow.
Confirmed speakers are: Prof Nicol Keith (Institute of Cancer Sciences, Glasgow), Prof Jacqui Shaw (University of Leicester) and Prof Charles Coombes (Imperial College, London).
More details will be available soon…
BioteXcel held the Circulating Biomarkers Conference 2014 in Dundee on 1st & 2nd October. In an effort to strengthen the link between emerging knowledge and technologies and personalized healthcare decision points, this conference brought together experts in the area of circulating biomarkers.
Experts presented in the areas of circulating tumour cells (CTCs), circulating micro-RNA (miRNA) and circulating free DNA (cfDNA) and how biomarkers can be used for better patient healthcare decisions.
Circulating biomarkers promise to enable minimally-invasive monitoring of health states in patients for specific predictive or prognostic information. The universe of molecular diagnostic technologies is expanding rapidly, based on access to sensitive detection technologies and emergence of highly effective targeted therapeutics. Yet the process of developing the next generation of molecular diagnostics is in flux as the value of molecular information is debated. An important part of the process of developing these promising diagnostics is the accurate analytical and clinical validation of biomarkers followed by demonstration of utility in the clinic and assessment of impact on health care costs.
The program explored this link in an effort to foster further collaborations that can potentially result in specialized tests, kits or devices to improve patient care for multiple diseases. This conference highlighted the latest developments in moving CTCs, cfDNA, and circulating miRNA from the bench to the bedside.
Invited experts addressed these questions and others in this exciting field. We hope that this conference contributed to move research on circulating biomarkers into diagnostics that will in turn aid in patient healthcare decisions.
Who should attend this Event?
… and all those interested in the latest developments of:
|09.30 – 10.30:||Registration, Coffee and Networking|
|10.30 – 10.45:||Opening|
|10.45 – 11.00:||Networking Mini Workshop|
|11.00 – 11.35:||Prof Jacqui Shaw,Translational Cancer Genetics, University of Leicester Circulating tumour DNA as a biomarker in breast cancer|
|11.35 – 12.10:||Technology Workshop: Using Reference Standards to analyse the sensitivity and specificity of assays optimised for cell-free DNA detection by Dr Hadas Raveh-Amit, Horizon Diagnostics|
|12.10 – 12.45:||Prof Sean Grimmond, Medical Genomics, Wolfson Wohl Cancer Research Centre, University of Glasgow Testing the clinical utility of personalised cancer genomics in advanced pancreatic cancer|
|12.45 – 13.45:||Lunch, Exhibition and Networking|
|13.45 – 14.20:||Prof Tim Meyer, Department of Oncology, UCL Cancer Institute, London – Talk Sponsored by Silicon BiosystemsSingle cell characterisation of neuroendocrine tumours|
|14.20 – 14.55:||Prof Caroline Dive, Cancer Research UK Manchester Institute CTC in lung cancer, Biology, Mouse models and Biomarkers|
|14.55 – 15.30:||Dr James Dear, Pharmacology, Therapeutics and Toxicology Unit, University of Edinburgh Biomarkers and stratified toxicology|
|15.30 – 16.00:||Coffee Break, Exhibition & Networking|
|16.00 – 16.35:||Prof Michael Kerin, Surgery and Head of Discipline at NUI Galway and Galway University Hospitals Discovery of circulating miRNA that differentiate breast cancer from other malignancies|
|16.35 – 17.00:||Dr Gillian Smith, Division of Cancer Research, Medical Research Institute, University of Dundee Novel clinical response biomarkers in drug-sensitive and drug-resistant ovarian cancer patients|
|17.00 – 17.35:||Dr Dana Tsui, Cancer Research UK Cambridge Institute Circulating tumour DNA for Non-invasive Cancer Management|
|18.00 – 19.00:||Civic Reception at City Chambers hosted by the Lord Provost of Dundee|
|19.30:||Networking Dinner (by prior booking only)|
|09.00 – 09.35:||Prof Charles Coombes, Medical Oncology, Imperial College London Breast Cancer: Progress in Monitoring Minimal Residual Disease|
|09.35 – 10.10:||Dr Alastair Greystoke, Medical Oncology, Newcastle upon Tyne NHS Foundation Trust Adaptive clinical trials in early drug development; potential and limitations of circulating biomarkers|
|10.10 – 10.45:||Technology Workshop: A novel approach for multiplexed ultrasensitive detection of somatic mutations in circulating cell-free tumor DNA by Dr Malcolm Plant, Agena Bioscience|
|10.45 – 11.15:||Coffee Break, Exhibition & Networking|
|11.15 – 11.50:||Prof Angie Cox, Academic unit of Molecular Oncology, University of Sheffield|
|11.50 – 12.25:||Prof Nicol Keith, Molecular Oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow Proof-of-concept biomarker integration into clinical trials|
|12.25 – 13.00:||Dr Dawn Coverley, Department of Biology, University of York & Cizzle Biotech Variant CIZ1 is a circulating biomarker for early stage lung cancer|
|13.00 – 14.00:||Lunch, Exhibition and Networking|
*PLEASE NOTE: The agenda may be subject to change
Cancer Research UK Manchester Institute
Professor of Translational Cancer Genetics, University of Leicester
Professor of Medical Oncology, Imperial College London
Head, Academic unit of Molecular Oncology, University of Sheffield
Medical Genomics, Wolfson Wohl Cancer Research Centre, University of Glasgow
Molecular Oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow
Surgery and Head of Discipline at NUI Galway and Galway University Hospitals
Molecular and Clinical Pharmacology, University of Liverpool
Reader, Department of Biology, University of York & Cizzle Biotech
Cancer Research UK Cambridge Institute
Lecturer in Medical Oncology, Newcastle upon Tyne NHS Foundation Trust
Silicon Biosystems, a wholly owned and operated subsidiary of the Menarini Group, is committed to improving research, diagnostic and therapeutic approaches to human health by enabling genetic analysis of important but rare cells associated with cancer disease.
Silicon Biosystems, S.p.A. manufactures and sells the DEPArray™ platform based on the principle of dielectrophoresis and offers the unique ability to control individual cells inside a disposable cartridge and to isolate pure rare and viable single cells based on a microelectronic array. The DEPArray™ platform makes it possible to find, sort, select and separate individual cells for further genetic analysis or culturing.
Silicon Biosystems, S.p.A. licensed and sells worldwide Ampli1 WGA KIT for whole genome amplification from single cell.
The company’s products are protected by a robust portfolio of patents. Products are marketed and sold directly, both in the US through our wholly-owned subsidiary, and in much of western Europe from our Italian headquarters. We maintain a network of distributors to serve the remainder of the global market.
For more information on Silicon Biosystems visit www.siliconbiosystems.com
Cambridge Bioscience is a leading distributor of life science products with a passion for bringing new and exciting technologies to researchers. Working with over 50 specialist suppliers around the world, we offer an innovative, extensive and diverse range of high quality products, services and instruments supporting research in the areas of next-generation sequencing, exosomes, molecular biology, epigenetics, cell culture, cell analysis and much more. Cambridge Bioscience – A Great Choice For Life Science Research.
The Parsortix system from ANGLE captures and harvests Circulating Tumour Cells (CTCs) from blood. The technology captures CTCs based on their larger size and more rigid structure compared to other blood components. It does not require the use of antibodies like a number of alternative techniques, and hence avoids problems associated with low antigen expression. The Parsortix system has been specifically designed with harvest of CTCs in mind to allow for their downstream genetic or protein analysis. CTCs are recovered in 200 µl of buffer with an extremely low level of background contamination. The system has been evaluated at CRUK – Manchester Institute and is currently being used for clinical research work at a number of leading research institutes both in Europe and in the US.
The system is CE marked for use in a clinical setting in Europe. For more information, please go to www.angleplc.com
Agena Bioscience GmbH designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include translational research, oncology and in vitro diagnostics for prenatal and retinal disorders.
Agena´s MassARRAY® technology is ideally suited for rapidly validating new genetic discoveries and translating them into innovative and cost effective genetic tests. The technology supports the analysis of multiple biomarkers and is applied by the leading genome centers worldwide.
Horizon Diagnostics (HDx), a business unit of Horizon Discovery Ltd, is a leading provider of genetically defined, human genomic reference standards, including FFPE cell line sections and purified gDNA. These standards offer a sustainable source of reference material to laboratories, proficiency schemes and manufacturers, providing an unprecedented level of control.
Genotypic tumor profiling is becoming increasingly routine in the battle against cancer, and next generation sequencing (NGS) is offering a way to quickly and affordably establish baseline tumor genetics. Platforms such as MiSeq™ and Ion Torrent™ are increasingly used to interrogate tumors using pre-defined cancer panels such as Ampliseq™ or Truseq™. The range of steps involved in a NGS workflow, combined with the sheer number of biomarkers being screened, has the potential to create unprecedented levels of variability. In order to generate results with confidence, it is therefore important to manage potential workflow variability from sample extraction and sample selection through to sequencing and variant calling.
In response to the growing number of scientists using NGS instruments to study tumor genetics, Horizon Diagnostics has developed a range of Quantitative Multiplex Reference Standards for general use. These highly defined reference standard contain engineered endogenous mutations, each calibrated by digital PCR to a chosen allelic frequency ranging between 0.5% and 25%.